Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Amplex Red Assays: Workflows, Uses, and Optimization
2026-09-04
Amplex Red converts low-level hydrogen peroxide and peroxidase activity into a measurable resorufin fluorescence signal, making it useful for cell assays, enzyme kinetics, and screening. This practical guide translates a cytochrome P450 engineering study into scalable assay design, with starting conditions and troubleshooting for reliable reactive oxygen species measurements.
-
Tomivosertib Workflows for MNK1 Inhibition
2026-09-04
Tomivosertib enables researchers to connect MNK1/2 target engagement with eIF4E phosphorylation, cancer-cell phenotypes, neuronal activity, and metabolic translation. This workflow-focused guide shows how to choose concentrations, pair molecular and functional readouts, and troubleshoot context-dependent results.
-
LY-411575: From Secretase Control to Translation
2026-09-03
LY-411575 connects amyloid biology with Notch-dependent tumor immunology. This thought-leadership analysis examines its mechanistic value, experimental boundaries, formulation considerations, and translational relevance for Alzheimer’s disease research and cancer research, including how recent TNBC findings reshape the case for pathway-aware gamma-secretase inhibition.
-
Cap 1 mRNA as a Translational Delivery Probe
2026-09-03
A thought-leadership perspective on using Cap 1 firefly luciferase mRNA to separate delivery, cytosolic release, translation, and cell-state effects, informed by recent IDP-inspired coacervate research.
-
Deferasirox Fe3+ chelate in Cell Assays
2026-09-02
A scenario-based guide to using Deferasirox Fe3+ chelate (SKU A3355) in cell viability, proliferation, and cytotoxicity workflows. It connects formulation constraints, solvent controls, assay interpretation, and recent mechanistic evidence to improve experimental comparability.
-
In Vitro Embryonic Dormancy Through mTOR Inhibition
2026-09-02
This Nature Protocols study establishes detailed in vitro workflows for reversibly placing mouse blastocysts, human blastoids, and mouse or human pluripotent stem cells into a diapause-like dormant state through pharmacological mTOR inhibition. Its main contribution is a scalable, noninvasive experimental framework that connects embryonic dormancy with transcriptional, translational, metabolic, and developmental readouts.
-
ZCL278: Selective Cdc42 Inhibitor Workflows
2026-09-01
ZCL278 gives researchers a time-resolved way to interrogate Cdc42 signaling in migration, neuronal morphology, and fibroblast activation models. This practical guide connects biochemical activity assays with imaging and functional readouts while highlighting dose, solvent, and interpretation safeguards.
-
Y-27632: A Translational ROCK Inhibition Strategy
2026-09-01
Y-27632 dihydrochloride connects Rho–ROCK biology with organoid engineering, stem cell viability, cytoskeletal control, and cancer research. This thought-leadership guide shows how translational teams can use a selective ROCK inhibitor to build more interpretable models while distinguishing established evidence from forward-looking applications.
-
CCT007093: Practical PPM1D Inhibitor Guide
2026-08-31
This scenario-driven guide explains how CCT007093 (SKU B3274) can improve interpretation of PPM1D, P38 MAPK, viability, and cytotoxicity experiments. It integrates biochemical, breast cancer, and kidney injury evidence with practical guidance on controls, DMSO handling, timing, and product selection.
-
Ridaforolimus for mTOR and Senescence Assays
2026-08-31
Ridaforolimus, also called Deforolimus or MK-8669, provides a potent, selective mTOR pathway perturbation tool for cancer-cell, angiogenesis, and senescence-model workflows. Its value is strongest when pathway inhibition is paired with orthogonal viability, apoptosis, and senescence readouts rather than interpreted from a single endpoint.
-
Mitochondrial Repair Platform for Diabetic Periodontitis
2026-08-30
The reference study develops a hierarchically targeted, ROS-responsive nanoparticle hydrogel that delivers MitoQ to dysfunctional mitochondria in pro-inflammatory M1 macrophages. Its local treatment strategy reduced inflammatory signaling and periodontal destruction in a diabetic periodontitis rat model, while also improving the osteogenic environment for alveolar bone repair.
-
Rifampin Workflows for Bacterial Transcription Studies
2026-08-29
Rifampin provides a direct, bactericidal way to perturb bacterial transcription for resistance, regulation, and synthetic biology experiments. This workflow-focused guide connects careful compound handling with assay design while clarifying how bacterial transcription studies differ from the light-controlled mammalian translation system described in the reference study.
-
Cy5 NHS ester(Et): Practical Labeling Guide
2026-08-28
Cy5 NHS ester(Et) (SKU A8769) is a water-soluble reagent for covalently fluorescently labeling primary amines on proteins, peptides, and related biomolecules. It is suitable for protein labeling, immunofluorescence, flow cytometry, and fluorescence microscopy, but not for ethanol-based protocols or long-term storage of working solutions.
-
PPZ1–TORC1 Ferroptosis in Candida albicans
2026-08-28
This study identifies a PPZ1–TORC1 regulatory axis that links lipophilic oxidant-induced ferroptosis with autophagy and antifungal resistance in Candida albicans. Its findings position fungal ferroptosis as a potential research direction while emphasizing that pathway-specific validation is needed before translating the mechanism into antifungal treatment strategies.
-
Oridonin Protects Bone via MAPK/NF-κB and BMP-2/RUNX2
2026-08-27
The 2023 reference study shows that oridonin counteracts thioacetamide-associated bone injury through two complementary mechanisms: suppressing MAPK/NF-κB-driven osteoclastogenesis and restoring BMP-2/RUNX2-associated osteoblast differentiation. Its dual-action design provides a useful preclinical framework for studying coordinated control of bone resorption and formation.